Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders.
Dublin-based Horizon Pharma will pay $46 per share for Brisbane, California-based Hyperion, marking a 5.6 percent premium to that stock's closing price on Friday.
The move adds the drugs Raviciti and Buphenyl to Horizon's offerings. Both drugs are aimed at treating inherited disorders called urea cycle disorders which affect about 2,100 people in the U.S. The genetic condition affects how the body removes nitrogen from the blood. Nitrogen buildup can be toxic.
Combined, the drugs had sales of $113.6 million in 2014.
Horizon has five products, of which Actimmune is focused on treating the genetic condition chronic granulomatous disease, which is a group of immune system conditions. It had sales of $25.3 million in 2014. The biotechnology company's biggest revenue comes from the rheumatoid arthritis and osteoarthritis treatment Vimovo, at $163 million in 2014.
Overall, Horizon had $297 million in nets sales from in 2014.
The companies expect the deal to close during the second quarter.
Shares of shares of Hyperion rose $2.76, or 6.5 percent to $45.50 in premarket trading while Horizon Pharma PLC rose $2.39, or 11 percent, to $24.20.
Explore further: Lexmark agrees to buy software maker Kofax for $1 billion
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Lexmark agrees to buy software maker Kofax for $1 billion
Printer maker Lexmark International will buy software developer Kofax Ltd. for about $1 billion.
SS&C Technologies to buy Advent Software for $2.29B
SS&C Technologies is buying Advent Software for $2.29 billion in a combination of providers of software for financial services companies.
Teva buying Auspex for $3.2 billion
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Endo Intl. tops Valeant's offer for fellow drugmaker Salix (Update)
Specialty drugmaker Endo International PLC is trying to lure Salix Pharmaceuticals Ltd. with an offer Endo said is worth 11 percent more than the $10 billion Salix has agreed to accept from serial acquirer Valeant Pharmaceuticals ...
Shire buys ViroPharma in $4.2 billion deal (Update)
The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.
Recommended for you
What to do with kidneys from older deceased donors?
A new study highlights the best way to use kidneys from older deceased donors, providing the most benefits to patients and addressing the worsening organ shortage. The study's findings, which appear in an upcoming issue of ...
Consent process for medical research conflicts with standard UK practice
A major investigation into the views of volunteers on the consent process for medical research has been found to conflict with the standard practice required for consent in the UK.
European nations sign world's first organ trafficking treaty
Fourteen European nations signed Wednesday in Spain the first ever international treaty to fight human organ trafficking, a business that generates over one billion dollars in illegal profits worldwide every year.
Research reveals biological barrage that corrodes orthopedic implants
About half a million people receive hip replacements worldwide every year. Of these, a small percentage will develop health complications due to their implant. Complications like inflammation and infection, ...
Team finds navigators are integral to clinical research process
A study reported in this week's Science Translational Medicine found that qualified investigators are more likely to respond to opportunities for clinical trials if they are contacted by an institution-specific point person ...
Economic benefits of medical innovation undervalued, study says
A new analysis co-written by a University of Illinois expert in health care economics concludes that increases in the pace of medical innovation reduce overall physical risks to health, and thus function ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders.
Dublin-based Horizon Pharma will pay $46 per share for Brisbane, California-based Hyperion, marking a 5.6 percent premium to that stock's closing price on Friday.
The move adds the drugs Raviciti and Buphenyl to Horizon's offerings. Both drugs are aimed at treating inherited disorders called urea cycle disorders which affect about 2,100 people in the U.S. The genetic condition affects how the body removes nitrogen from the blood. Nitrogen buildup can be toxic.
Combined, the drugs had sales of $113.6 million in 2014.
Horizon has five products, of which Actimmune is focused on treating the genetic condition chronic granulomatous disease, which is a group of immune system conditions. It had sales of $25.3 million in 2014. The biotechnology company's biggest revenue comes from the rheumatoid arthritis and osteoarthritis treatment Vimovo, at $163 million in 2014.
Overall, Horizon had $297 million in nets sales from in 2014.
The companies expect the deal to close during the second quarter.
Shares of shares of Hyperion rose $2.76, or 6.5 percent to $45.50 in premarket trading while Horizon Pharma PLC rose $2.39, or 11 percent, to $24.20.
Explore further: Lexmark agrees to buy software maker Kofax for $1 billion
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Lexmark agrees to buy software maker Kofax for $1 billion
Printer maker Lexmark International will buy software developer Kofax Ltd. for about $1 billion.
SS&C Technologies to buy Advent Software for $2.29B
SS&C Technologies is buying Advent Software for $2.29 billion in a combination of providers of software for financial services companies.
Teva buying Auspex for $3.2 billion
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Endo Intl. tops Valeant's offer for fellow drugmaker Salix (Update)
Specialty drugmaker Endo International PLC is trying to lure Salix Pharmaceuticals Ltd. with an offer Endo said is worth 11 percent more than the $10 billion Salix has agreed to accept from serial acquirer Valeant Pharmaceuticals ...
Shire buys ViroPharma in $4.2 billion deal (Update)
The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.
Recommended for you
What to do with kidneys from older deceased donors?
A new study highlights the best way to use kidneys from older deceased donors, providing the most benefits to patients and addressing the worsening organ shortage. The study's findings, which appear in an upcoming issue of ...
Consent process for medical research conflicts with standard UK practice
A major investigation into the views of volunteers on the consent process for medical research has been found to conflict with the standard practice required for consent in the UK.
European nations sign world's first organ trafficking treaty
Fourteen European nations signed Wednesday in Spain the first ever international treaty to fight human organ trafficking, a business that generates over one billion dollars in illegal profits worldwide every year.
Research reveals biological barrage that corrodes orthopedic implants
About half a million people receive hip replacements worldwide every year. Of these, a small percentage will develop health complications due to their implant. Complications like inflammation and infection, ...
Team finds navigators are integral to clinical research process
A study reported in this week's Science Translational Medicine found that qualified investigators are more likely to respond to opportunities for clinical trials if they are contacted by an institution-specific point person ...
Economic benefits of medical innovation undervalued, study says
A new analysis co-written by a University of Illinois expert in health care economics concludes that increases in the pace of medical innovation reduce overall physical risks to health, and thus function ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment